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ABSTRACT: Pulsatilla vulgaris Mill. (“Pasque flower”, Ranunculaceae) is rare and a threatened plant 
species in Europe. It produces biologically active secondary metabolites. P. vulgaris is also known herbal drug 
used for centuries in traditional Chinese and Korean medicine. The rhizomes of P. vulgaris have been 
traditionally used for treatment of headaches, neuralgia, insomnia, hyperactivity, bacterial skin infections, 
septicemia, cough and bronchitis. In the present study, the extracts of leaves and rhizomes of P. vulgaris were 
evaluated for their antifungal, antimicrobial, antimalarial and cytotoxic activities. The results showed the 
antifungal activity of crude extracts of the rhizome of P. vulgaris against the yeast Candida glabrata with an 
IC50 of 11 µg/ml. These results indicate that the selected medicinal plant could be further investigated for 
identifying compounds that may be responsible for the observed activity and that may represent new leads in 
fungal drug discovery. 
Keywords: Pulsatilla vulgaris subsp. vulgaris; Ranunculaceae; Leaves and rhizomes extracts; Biological 
activity; Microbiological assays. 
1. INTRODUCTION 
 Phytochemical studies of Pulsatilla species revealed the presence of a high diversity of secondary 
metabolites [1]. Many bioactive compounds have been reported from the extract of Pulsatilla species such as 
anemonin [2] and protoanemonin [3, 4], hederagenin [5], oleanolic saponins and lupane-type saponins [6, 7] 
and antimicrobial cinnamic acid derivatives [8] or anti-acne activities of pulsaquinone, hydropulsaquinone 
and 1,4-quinone derivatives [9]. The triterpene saponins were isolated from P. chinensis (Bunge) Regel               
[10-12], P. koreana Nakai [2, 6, 13], P. cernua (Thunb.) Bercht. et Opiz. [14, 15], P. dahurica (Fisch. ex DC.) 
Spreng. [16], P. turczaninovii Kryl. et Serg. [17], P. nigricans Storck [18], P. pratensis (L.) Mill. [19] and              
P. patens subsp. multifida (G.A. Pritzel) Zämelis [20] (Table 1). Polyphenolic compounds such as flavonoids 
and anthocyanidins are produced by P. montana subsp. balcana (Velen.) Zämelis & Paegle, P. halleri subsp. 
rhodopaea (Stoj. et Stef.) K. Krause and P. slaviankae (Zimmer.) Jordanov & Kožuharov [21]. 
Chromatographic fractionation of the root extract from P. patens subsp. patens (L.) Mill. collected in Poland 
resulted in the isolation of three known oleanane-type glycosides identified as hederagenin 3-O-β-D-
glucopyranoside, hederagenin 3-O-β-D-galactopyranosyl-(1→2)-β-D-glucopyranoside [22], and saponin D 
[23]. In the course of our studies on medicinal plants we evaluated the extracts of leaves and rhizomes of 
Łaska & Sienkiewicz   Antifungal activity of Pulsatilla vulgaris against Candida glabrata 94 
Eur. J. Biol. Res. 2019; 9(2): 93-103 http://www.journals.tmkarpinski.com/index.php/ejbr 
Pulsatilla vulgaris Mill. for their antifungal, antimicrobial, antimalarial activities, and cytotoxicity to 
mammalian cell lines.    
 
Table 1. Common Pulsatilla species in medicine. 
Species Action Main components References 
Pulsatilla patens subsp. multifida 
 
antifungal 
antimicrobial 
antitumor/cytotoxic 
molluscicidal 
antidiabetic 
antileishmanial 
 
triterpene saponins 
[20] 
Pulsatilla koreana [2, 6, 13] 
Pulsatilla chinensis [10-12] 
Pulsatilla cernua [14, 15] 
Pulsatilla dahurica [16] 
Pulsatilla turczaninovii [17] 
Pulsatilla montana subsp. balcana 
antioxidant 
antibacterial 
antifungal 
antiviral 
hepatoprotective 
anticancer 
anti-inflammatory 
phenolics 
flavonoids 
anthocyanidins 
[21] 
 
 The species of P. vulgaris was not extensively studied. Although the first report on pharmacodynamic 
properties, the distribution of saponins and tannins in this plant as well as pharmacology of isolated 
compounds came in 20th and 40th of the last century [24-26], they were followed only recently by few works 
on physiology [27, 28], genetic characteristics of the species [29, 30], ecology [31, 32] and various aspects of 
developmental biology [33]. In the fresh leaves and rhizomes of P. vulgaris the presence of the glycoside 
ranunculin was observed, which is converted to anemonine when the plant is dried [34, 35]. GC-MS analysis 
of the silylated methanolic extract of the leaves and rhizomes of P. vulgaris in our laboratories revealed the 
presence of carboxylic acids, such as benzoic, caffeic, malic, and succinic acids [5].  
 Relevant pharmacologic information regarding P. vulgaris is very scarce [9, 36-38]. However, the 
study done by Saify et al. [39] demonstrates the ability of P. vulgaris to reduce smooth muscle spasm. The 
extract from plant material appears to support the traditional use of this species as an antispasmodic [39]. This 
extract also can protect human cells against combined xenobiotic effects [40]. An important active constituent 
of P. vulgaris is protoanemonin [41-43]. Protoanemonin has been reported to have antibacterial, antimalarial 
and antifungal activity, however, it has been found to be cytotoxic as well. Plant extract from P. vulgaris 
showed antibacterial activity and inhibited the growth of Escherichia coli, Staphylococcus aureus and 
Candida albicans [44]. Due to the lack of current pharmacologic information about this species a study that 
examined the effect of protoanemonin which was extracted from P. chinensis was reviewed. Pharmacological 
study of secondary metabolites from P. chinensis showed that this compound possess anti-inflammatory affect 
on intestinal cells [45]. Additionally, analyses of biologically active metabolites from P. koreana showed that 
protoanemonin possesses antifungal activity and acts as an antibiotic [46]. Kanetoshi et al. [37] estimated that 
plant extract from P. vulgaris contains anticancer components active to three cell lines. 
 P. vulgaris is confined to dry grasslands, in sparsely wooded pine forests or meadows, often on a sunny 
sloping side with calcium-rich soil, where it grows at an altitude between 110-580 m. It grows well in fertile, 
humusy, gritty, and medium moisture well-drained soils in full sun to light shade. The best performance 
occurs in cool climates where plants are also more apt to tolerate drier conditions. There are three 
distinguishing subspecies of P. vulgaris, P. vulgaris subsp. vulgaris, subsp. grandis (Wender.) Zamels and 
subsp. gotlandica (Johanss.) Zamels & Paegle. 
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2. MATERIALS AND METHODS 
2.1. Plant material 
 The leaves and rhizomes of P. vulgaris subsp. vulgaris were obtained from cultivation at the 
Herbarium “The Herbal Corner” located in Podlaskie Province, in North-Eastern Poland in May 2013 and 
identified by Prof. Grażyna Łaska from the Bialystok University of Technology, Faculty of Civil and 
Environmental Engineering, Poland.  
2.2. General experimental procedures 
 The plant material in the form of crude rhizomes (56.1 g) and leaves (21.8 g) was extracted by 
accelerated solvent extraction (ASE) method (Buchi E-916) with 80% methanol and evaporated under 
reduced pressure. The crude extracts of rhizomes (0.8 g) and leaves (0.7 g) were resolved in 99.8% methanol 
and analyzed for their antimicrobial and antimalarial activities. The rhizome extract was also tested for 
cytotoxicity against cancer and healthy mammalian cell lines. 
2.3. Antimicrobial assay 
 All organisms were obtained from the American Type Culture Collection (Manassas, VA) and include 
the fungi Candida albicans ATCC 90028, C. glabrata ATCC 90030, C. krusei ATCC 6258, Cryptococcus 
neoformans ATCC 90113, and Aspergillus fumigatus ATCC 204305 and the bacteria Staphylococcus aureus 
ATCC 29213, methicillin-resistant S. aureus ATCC 33591 (MRS), Escherichia coli ATCC 35218, 
Pseudomonas aeruginosa ATCC 27853, and Mycobacterium intracellulare ATCC 23068. Susceptibility 
testing was performed using a modified version of the CLSI (formerly NCCLS) methods [47-50].                              
M. intracellulare was tested using a modified method of Franzblau et al. [51]. Samples were serially-diluted 
in 20% DMSO/saline and transferred in duplicate to 96-well flat bottom microplates. Microbial inocula were 
prepared by correcting the OD630 of microbe suspensions in incubation broth to afford final target inocula. 
Drug controls [Ciprofloxacin (ICN Biomedicals, USA) for bacteria and Amphotericin B (ICN Biomedicals, 
Ohio) for fungi] were included in each assay. All organisms were read at either 530 nm using the Biotek 
Powerwave XS plate reader (Bio-Tek Instruments, Vermont) or 544 ex/590 em, (M. intracellulare,                             
A. fumigatus) using the Polarstar Galaxy Plate Reader (BMG LabTechnologies, Germany) prior to and after 
incubation. Minimum fungicidal or bactericidal concentrations were determined by removing 5 µL from each 
clear well, transferring to agar and incubating. The MFC/MBC was defined as the lowest test concentration 
that kills the organism (allows no growth on agar). 
2.4. Assay for antimalarial activity  
 The antimalarial activity was determined against chloroquine sensitive (D6) strain of Plasmodium 
falciparum by measuring plasmodial LDH activity according to the procedure of Makler and Hinrichs [52]. A 
suspension of red blood cells infected with P. falciparum (200 µL, with 2% parasitemia and 2% hematocrit in 
RPMI 1640 medium supplemented with 10% human serum and 60 µg/ml amikacin) was added to the wells of 
a 96‐well plate containing 10 µl of diluted sample. The plate was incubated at 37oC, for 72 h in a modular 
incubation chamber with 90% N2, 5% O2, and 5% CO2. Parasitic LDH activity was determined by mixing 20 
µl of the incubation mixture with 100 µl of the MalstatTM reagent (Flow Inc., Portland, OR) and incubating 
at room temperature for 30 min. Twenty microliters of a 1:1 mixture of NBT/PES (Sigma, St. Louis, MO) was 
then added and the plate was further incubated in the dark for 1 h. The reaction was then stopped by adding 
100 µl of a 5% acetic acid solution and the absorbance was read at 650 nm. Artemisinin and chloroquine were 
included as the drug controls. IC50 values were computed from the dose response curves of growth inhibition 
using XLfit 4.2 (IDBS, USA). 
 
Łaska & Sienkiewicz   Antifungal activity of Pulsatilla vulgaris against Candida glabrata 96 
Eur. J. Biol. Res. 2019; 9(2): 93-103 http://www.journals.tmkarpinski.com/index.php/ejbr 
2.5. Assay for cytotoxicity 
 The in vitro cytotoxicity of the rhizome extract was determined against a panel of cancer and non-
cancer cell lines. The assay was performed in 96‐well tissue culture‐treated plates. The cells were seeded to 
the wells of 96‐well plate at a density of 25,000 cells/well and grown for 24 h. Samples at different 
concentrations were added and cells were further incubated for 48 h. Cell viability was determined by Neutral 
Red method [53]. IC50 values were obtained from dose response curves. Doxorubicin was included as drug 
control.  
3. RESULTS 
 Microbiological assays of the rhizome extracts of P. vulgaris showed activity against fungal pathogen 
Candida glabrata with an IC50 value of 11 µg/ml. The results of all antimicrobial activity tests are shown in 
Tables 2 and 3.   
 
Table 2. The test results of the antimicrobial activity of rhizomes and leaves extracts of Pulsatilla vulgaris Mill. (primary 
screen). 
Tested strain Extracts from rhizomes           (50 µg/ml) 
Extracts from leaves 
(50 µg/ml) 
Amphotericin B  
(5 µg/ml) 
Ciprofloxacin  
(1 µg/ml) 
C. albicans 24 11 100 ND 
C. glabrata 98 14 100 ND 
C. krusei 16 15 100 ND 
A. fumigatus 11 21 99 ND 
C. neoformans 40 0 82 ND 
S. aureus 16 7 ND 89 
MRSA 9 9 ND 94 
E. coli 24 20 ND 96 
P. aeruginosa 11 7 ND 100 
M. intracellulare 0 0 ND 72 
The results in %, ND – not determined.         
 
Table 3. Dose response (IC50 in µg/ml) results of the rhizome extracts of Pulsatilla vulgaris Mill. 
Test strain Extracts from rhizomes Amphotericin B Ciprofloxacin 
C. albicans NA 0.19 ND 
C. glabrata 11 0.37 ND 
C. krusei NA 0.67 ND 
A. fumigatus NA sty.17 ND 
C. neoformans NA 0.18 ND 
S. aureus NA ND 0.09 
MRS NA ND 0.08 
E. coli NA ND 0.01 
P. aeruginosa NA ND 0.07 
M. intracellulare NA ND 0.37 
The results in IC50, ND – not determined, NA – not active at 200 µg/ml.     
  
 The extracts from the rhizomes and leaves of P. vulgaris showed decreased ability to inhibit the 
growth of the other bacteria (Staphylococcus aureus, MRSA, Escherichia coli, Pseudomonas aeruginosa), and 
four different fungi (Candida albicans, Candida krusei, Aspergillus fumigatus, Cryptococcus neoformans) 
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pathogenic to humans. These extracts did not show any ability to inhibit the growth of the bacteria 
Mycobacterium intracellulare (Tables 2-3).  
 Antimalarial assays of the extracts from the rhizomes and leaves of P. vulgaris showed very low 
activity (1-8% of inhibition) against the protozoan, when the antimalarial drug chloroquine (positive control) 
showed 94-98% of inhibition.  
 The rhizome extract showed cytotoxicity to all the cell lines included in the assay. As shown in Table 
4, the IC50 for cytotoxicity was in the range of 35-57 µg/ml for each cell line indicating a general cytotoxic 
activity throughout the panel of cancer and non-cancer cells. 
 
Table 4. Cytotoxicity of Pulsatilla vulgaris Mill. rhizome extract towards a panel of mammalian cell lines. 
Sample name 
IC50 µg/ml 
SK-MEL KB BT-549 SK-OV-3 LLC-PK1 Vero 
Rhizome extract 44 42 57 35 42 39 
Doxorubicin* 1.7 1.7 2.2 2.3 1.6 >5 
Cell lines: SK-MEL - skin melanoma, KB - epidermal carcinoma, BT-549 - breast cancer, SK-OV-3 - ovarian cancer, 
LLC-PK1 - kidney epithelial, Vero - kidney fibroblast. *positive control drug 
 
4. DISCUSSION 
 The Pulsatilla species (Ranunculaceae) produces a high diversity of secondary metabolites with a 
biological activity. The triterpene saponins, flavonoids and anthocyanidins from various Pulsatilla subsp. have 
demonstrated multiple biological properties including antitumor [46, 54, 55], cognition-enhancing [56, 57], 
neuroactive [58], neuroprotective [59], immunomodulatory [60], antioxidant [61], antimicrobial [20] and 
cytotoxic [12] activities. Additionally, they have potential beneficial effects as a chemopreventive agent for 
critical health conditions including cancer. Treatment with Pulsatilla saponin D resulted in inhibition of cell 
growth/proliferation, angiogenesis and induction of apoptosis in cancer [62]. Pulsatilla saponin D isolated 
from the root of Pulsatilla koreana Nakai showed potent inhibition rate of tumor growth (IR, 82%) at the dose 
of 6.4 mg/kg on the BDF1 mice bearing LLC cells [6]. The extracts of the rhizomes or roots from other 
species of the Pulsatilla species have been used for amoebic, dysentery, malaria, epistaxis, and internal 
hemorrhoids [9]. 
 The fact that Pulsatilla species produce the high content of a variety of secondary metabolites allows 
an intense search for new natural-product derived drugs, especially new antibiotics and antifungal agents. It is 
very important because currently used antifungal drugs are not effective in 15-20% of cases against Candida 
glabrata [63]. Candida glabrata (H.W. Anderson) S.A. Mey & Yarrow (1978) is a pathogenic ascomycete 
yeast, which is the second most frequent causative agent of human candidiasis [63]. C. glabrata is an 
opportunistic pathogen of the urogenital tract, and of the bloodstream. It is especially aggressive in HIV 
positive people, and the elderly [64]. There are two potential virulence factors that contribute to the 
pathogenicity of C. glabrata. The first is a series of adhesins coded by the EPA (epithelial adhesin) genes. 
These genes, located in the subtelomeric region, can respond to environmental cues that allow them to be 
expressed “en masse” so the organism can adhere to biotic and abiotic surfaces in microbial mats. This is also 
the suspected mechanism by which C. glabrata forms microbial “biofilms” on urinary catheters, and less 
commonly in-dwelling catheters. It also causes problems with dental devices, such as dentures [64]. 
 Although C. glabrata is listed as the second most virulent yeast after Candida albicans, little 
information is available regarding its identification and treatment of infection. A major phenotype and 
potential virulence factor that C. glabrata possesses is low-level intrinsic resistance to the azole drugs, which 
are the most commonly prescribed antifungal medications. These drugs, like fluconazole and ketoconazole, 
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are not effective in 15-20% of cases against C. glabrata [63]. It is still highly vulnerable to polyene drugs 
such as amphotericin B and nystatin, along with variable vulnerability to flucytosine and caspofungin. 
Amphotericin B vaginal suppositories are used as an effective form of treatment in combination with boric 
acid capsules as they are not absorbed into the blood stream. Amphotericin B vaginal suppositories have also 
been used in case studies to treat chronic infections, both symptomatic and asymptomatic [63]. However high 
renal toxicity and other side effects of amphotericin B contained drugs make the use of such therapy the last 
resort approach. In the light of the limitation of existing antifungal therapy against C. glabrata the search for 
new safer drugs and natural products-derived agents or herbal preparations is highly desirable. The high 
antifungal activity (IC50 11 µg/ml) of crude rhizome extracts of P. vulgaris against C. glabrata and the 
relatively high cytotoxicity (IC50 35-57 µg/ml) towards a panel of mammalian cell lines prompts further 
research on isolation and identification of biologically active components from this species. The designated 
activity of rhizome extract of P. vulgaris below the threshold of observed toxicity qualify this species for 
further studies toward homeopathic therapy of candidiasis caused by pathogenic C. glabrata.  
 In 2015, the application for an invention patent titled “The use of Pulsatilla vulgaris Mill. in the 
treatment of fungal diseases” was submitted to the Polish Patent Office by the authors of this publication. 
Pharmaceutical application of extracts from P. vulgaris was patented by other authors [65-67]. The first 
invention provides an herbal extract pharmaceutical composition including P. vulgaris and its use in medicine. 
The application of this therapeutic extract increases the effectiveness in treating bloating. The second 
invention relates to an herbal composition comprising extract from P. vulgaris and use of this for preventing 
or treating skin diseases. The next application as antimicrobial composition includes an effective extract of 
plant of the Ranunculaceae family in that P. vulgaris. 
 The genus Pulsatilla comprises about 30 species, but P. vulgaris is an allotetraploid (2n=32) and may 
have occurred following hybridization between P. patens (2n=16) and P. pratensis (2n=16) [68]. Pulsatilla 
vulgaris Mill. is an early-flowering, long-lived, polycarpic hemicryptophyte herb of conservation concern and 
specialist species of calcareous grasslands across central Europe, ranging from France in the south to Sweden 
at its northern limit [33]. The current range this species is characterized by a high level of fragmentation, since 
numbers and sizes of populations have declined considerably during the last few decades, mainly as a 
consequence of land-use changes [29]. The reasons for the loss this species include mainly ploughing-up of 
calcareous grassland [31], cessation of traditional grazing practices [69], increased above-ground competition 
from coarse grasses and shrubs, what caused impossibility colonized restored habitats [32]. Consequently, 
small and fragmented populations showed signs of genetic depauperation due to genetic drift [29].  
 Numerous applications of P. vulgaris in traditional medicine are one of the reasons for reducing the 
abundance of this species. P. vulgaris is listed as “near threatened” by the International Union for 
Conservation of Nature [70]. Currently P. vulgaris is listed as vulnerable (VU category) in Ukraine, Slovakia 
[71], Sweden [72] and United Kingdom [73]. In Germany, it is classified as lower risk (LR category), 
however subsp. grandis (Wender.) Zamels listed as critically endangered (CR category) and 
subsp. vulgaris listed as endangered (EN category) [74]. This species is also listed as endangered (EN 
category) in Switzerland [75] and as critically endangered (CR category) in Austria [76]. In the “Red List of 
Vascular Plants in Poland” [77] and “Polish Red Data Book of Plants” [78] it is classified as extinct (EX 
category) species. In order to obtain larger amount of plant material for future study, a cooperation agreement 
was signed between the Bialystok University of Technology and Botanical Garden “Herbal Corner”, from 
where cultivated plant species were transferred from the Botanical Garden to our laboratories.  
 P. vulgaris in Poland is mainly cultivated. In Denmark, Germany and Sweden it is still relatively 
widespread, but appears to have declined, especially in Sweden [72] and Germany, where it’s populations are 
now small and highly fragmented [29]. In Austria, only around 2000 plants now survive in 23 sites [79] and 
Switzerland where it is very rare [33]. In Belgium it is confined to two small areas (Quentin Groom, pers. 
comm.). In Luxembourg it is declined from 28 to 5 localities [80]. In England P. vulgaris is a threatened herb 
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that declined from 130 to 33 sites between 1750 and the 1960s [31]. P. vulgaris appears to be extinct in 
Finland, where it has not been seen since the 1930s [81].  
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